Antiproliferative activity and apoptosis induced by 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline on cells of leukemia lines by Jantova, S. et al.
Experimental Oncology ��� �������� ���� ���ne� ���
Q�inazoline derivatives are known to possess a 
broad spectr�m of biological activities and are �sed 
in pharmace�tical ind�stry� in medicine and in agri-
c�lt�re beca�se of their antimicrobial� antiinflamma-
tory� di�retic� anticonv�lsant� antiallergic� and other 
properties [�� �]. As doc�mented in the literat�re� 
many derivatives of q�inazoline act as anticancer 
dr�gs [�� �]. They act as m�ltitarget agents possess-
ing inhibitory activities against thymidylate synthase� 
dihydrofolate red�ctase� tyrosine kinase� and cyclic 
GMP phosphodiesterase [5�7]. Some q�inazolines 
interact with cytoskeleton� ind�ce apoptosis and inhibit 
DNA topoisomerase [����].
Based on the above-mentioned effects of q�inazo-
lines� a new series of s�bstit�ted �-anilinoq�inazolines 
was prepared by Stankovsky et al. [�����]. These com-
po�nds were screened for antibacterial� m�tagenic 
and cytotoxic activities in vitro. 6-bromo-�-�morpholin-
�-yl�-�-anilinoq�inazoline �BMAQ� was fo�nd be the 
most potent derivative. This dr�g inhibited the growth 
of HeLa and B-�6 cells and ind�ced changes in actin 
of HepG� cells [��� ��].
The aim of this st�dy was to eval�ate the anticancer 
activity of BMAQ towards selected le�kemia cells� i. e. 
m�rine L����� h�man promyelocytic HL-6� and h�man 
promonocytic U-��7 le�kemia cells. Additionally� the 
effects of BMAQ on cell cycle and its potential to in-
d�ce apoptosis were st�died.
MATERIALS AND METHODS
Drug. 6-bromo-�-�morpholin-�-yl�-�-anilinoq�i-
nazoline �BMAQ� �Fig. �� was synthesized according 
to Stankovsky et al. [��� ��]. The sol�tion of BMAQ 
��� mM in ���% DMSO� was stored at ��� °C� protec-
ted from light. The final concentration of DMSO in the 
medi�m was < �.5% and did not affect cell growth.
Fig. 1. Chemical str�ct�re of 6-bromo-�-�morpholin-�-yl�-�-
anilinoq�inazoline �BMAQ�
Cell line. M�rine L���� le�kemia cells� h�man pro-
myelocytic HL-6� le�kemia cells and h�man promono-
cytic U-��7 le�kemia cells �ATCC� Rockville� MD� USA� 
were grown in RPMI-�6�� medi�m s�pplemented with 
��% FCS� ��� �nits/ml penicillin� ��� µg/ml strepto-
mycin and � mM L-gl�tamine in an atmoshere of 5% 
CO� in h�midified air at �7 °C.
Drug treatment. Exponentially growing cells were 
harvested by centrif�gation and res�spended in fresh 
medi�m to achieve c�lt�re density of � x ���/ml for 
L����� � x ��5/ml for HL-6� and � x ��5/ml for U-��7 
cells. The cells were treated with �.�6����.� µM BMAQ 
for ��� �� and 7� h. Cell n�mber and viability were 
determined by trypan bl�e staining.
Cell cycle measurement. Untreated and dr�g-
treated cells ��.5 x ��6� were harvested� washed 
twice in PBS and exposed to �.�5% Triton X-��� 
in PBS s�pplemented with RNAse �5� µg/ml� for 
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�5 min at �7 °C. Afterwards� DNA was stained by PI 
�5� µg/ml� for �5 min at � °C. Samples were analyzed 
by a Beckman-Co�lter FC 5�� flow cytometer �Beck-
man Co�lter Inc� F�llerton� California� USA� with the 
�se of DNA Cell Cycle Analysis Software distrib�ted by 
Phoenix Flow Systems — M�ltiCycle AV for Windows. 
A minim�m of ����� cells per sample were analyzed 
at a flow rate of ��� cells/s.
Analysis of apoptotic DNA fragmentation. Un-
treated and dr�g-treated cells �� x ��6� were harvested� 
washed in PBS and lysed with ��� µl of sol�tion ��� mM 
Tris� �� mM EDTA� �.5% Triton X-���� s�pplemented with 
proteinase K �� mg/ml�. Samples were inc�bated at �7 °C 
for � h and heated at 7� °C for �� min. Following lysis� 
RNAse ���� µg/ml� was added and repeated inc�bation 
at �7 °C for � h followed. The samples were s�bjected to 
electrophoresis at �� V for � h in �.�% �w/v� agarose gel 
complemented with EtBr ��µg/ml�. Separated DNA frag-
ments were vis�alized �sing UV transill�minator.
Fluorescence microscopy. Untreated and dr�g-
treated cells were res�spended in � ml of fresh medi�m 
and �� µl of Hoechst �� �5� �� µg/ml� and �5 µl of PI 
�5 µg/ml� were added. Cell s�spension was inc�bated 
for �� min at RT. Cells were centrif�ged� res�spended 
in �� µl of fresh medi�m and monitored by fl�orescence 
microscopy �Zeiss �enal�mar� �ena� Germany�.
Caspase-3 activity assay. Cells were treated with 
vehicle �DMSO� or ��� µM BMAQ for �� h. Cell lysates 
were prepared and caspase-� activity was meas�red 
according to the man�fact�rer`s protocol �CaspACETM 
Assay System Colorimetric� Promega Corporation� 
USA�. Briefly� an eq�al amo�nt of cell lysate proteins 
�adj�sted to �� µl with lysate b�ffer� was added to the 
reaction mixt�res containing colorimetric s�bstrate 
peptide specific for caspase-� �Ac-DEVD-pNA�. The 
plate was inc�bated in the dark for �� h at �7 °C. Ab-
sorbance at ��5 nm was determined �sing microplate 
reader �H�mareader� Wiesbaden� SRN�. Protein con-
centration was determined by Lowry method [�5].
RESULTS
BMAQ inhibits growth and induces cell cycle pro-
file changes. Proliferation of L����� HL-6� and U-��7 
le�kemia cells exposed to �.�6���� µM of 6-bromo-
�-�morpholin-�-yl�-�-anilinoq�inazoline �BMAQ� was 
monitored within ��� �� and 7� h. As shown in Table �� 
BMAQ ind�ced concentration- and time-dependent 
inhibition of cell proliferation. After �� h of treatment� the 
highest tested concentration of BMAQ ���� µM� com-
pletely inhibited cell division and after 7� h� part of cell 
pop�lation degenerated. Assessment of cytoplasmic 
membrane integrity by trypan bl�e staining revealed that 
BMAQ did not affect the membrane integrity of le�kemia 
cells significantly �data not shown�.
As antiproliferative activity of anticancer dr�gs is con-
nected with cell cycle arrest� in the next experiments we 
checked the cell cycle profile of BMAQ-treated le�kemia 
cells. As presented in Table �� BMAQ ind�ced G�/M cell cy-
cle arrest of L���� �P < �.�5� and HL-6� cells. U-��7 cells 
were fo�nd to be arrested in G�/G� phase �P < �.�5�.
BMAQ induces apoptosis of leukemia cells. To 
eval�ate the type of cell death ind�ced by BMAQ� we 
analyzed the cells treated with BMAQ for markers related 
to programmed cell death. As shown in Fig. �� ��� µM 
BMAQ ind�ced significant apoptosis represented by 
typical patern of intern�cleosomal DNA fragmentation. 
The do�ble staining of treated cells by Hoechst and 
PI revealed the apoptotic bodies formation in treated 
le�kemia cells �Fig. ��. Additionally� the activation of cas-
pase-� was confirmed by colorimetric assay �P < �.��� 
�Fig. ��.
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Fig. 2. Electrophoretic analysis of intern�cleosomal DNA frag-
mentation of A: L����� B: HL-6� and C: U-��7 le�kemia cells 
treated with 6-bromo-�-�morpholin-�-yl�-�-anilinoq�inazoline 
�BMAQ� for �� h. Pt = 6.� µM cisplatin. Fig�re is representative 
of three independent experiments
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Fig. 3. Detection of apoptotic body formation in L����� HL-6� 
and U-��7 le�kemia cells treated with ���.� µM of 6-bromo-
�-�morpholin-�-yl�-�-anilinoq�inazoline �BMAQ� for �� h by 
fl�orescent microscopy �magnification = 6�� X�
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Fig. 4. Activity of caspase-� after �� h treatment of le�kemia 
cells with the ���.� µM of 6-bromo-�-�morpholin-�-yl�-�-ani-
linoq�inazoline �BMAQ�. Pt = 6 µM cisplatine. Data represent 
mean val�es ± s. d. of three independent experiments 
*P < �.��� **P < �.���.
DISCUSSION
Recently we have synthetized a series of s�bstit�ted 
�-anilinoq�inazolines. Some of these compo�nds showed 
biological activities towards bacteria and cancer cells [��� 
��]. Altho�gh 6-bromo-�-�morpholin-�-yl�-�-anilinoq�i-
nazoline �BMAQ� did not possess antibacterial activities� 
this derivative manifested significant antiproliferative acti-
vity towards HeLa� B-�6 and HepG� cells [��].
In this st�dy� we monitored the anticancer activity 
of BMAQ towards m�rine L����� h�man promyelocytic 
HL-6� and h�man promonocytic U-��7 le�kemia cells. We 
fo�nd that BMAQ inhibits proliferation of all tested le�ke-
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mia cells in time- and concentration- dependent manner 
�see Table ��. This finding is consistent with o�r previo�s 
observation that BMAQ can significantly red�ced the 
growth of HeLa� B-�6 and HepG� cells [��]. The fact that 
antiproliferative activities of anticancer dr�gs is connected 
with cell cycle changes prompted �s to analyze the cell 
cycle profile of BMAQ-treated le�kemia cells. We fo�nd 
that cell treated with the dr�g are arrested in G�/M phase 
�L���� and HL-6� cells� or in G�/G� phase �U-��7 cells� 
�see Table ��. Altho�gh we do not know reason for different 
effects of BMAQ on cell cycle profile of le�kemia cells� it 
is likely that the differences in cell cycle pert�rbation are 
d�e to differences in responce of partic�lar le�kemia cells 
to this dr�g. The experiments el�cidating the effects of 
BMAQ on cell cycle reg�latory proteins �e. g. cyclins and 
cyclin-dependent kinases� are c�rrently in progress.
Table 1. The values of IC50 and IC100 of 6-bromo-2-(morpholin-1-yl)-4-
anilinoquinazoline (BMAQ) towards L1210, HL-60 and U-937 cells after 
24, 48 and 72 h treatment
24 h 48 h 72 h
IC50 IC100 IC50 IC100 IC50 IC100
L1210 35.8 ± 1.4 > 104.0 13.3 ± 0.5 104.0 ± 1.6 10.9 ± 0.7 104.0 ± 1.2
HL-60 47.1 ± 2.8 > 104.0 15.3 ± 0.9 > 104.0 13.8 ± 0.8 104.0 ± 1.8
U-937 37.7 ± 1.9 > 104.0 13.7 ± 0.8 104.0 ± 1.7 12.0 ± 0.8 104.0 ± 1.9
Note. Data represent mean values ± s. d. (µM) of three independent 
experiments.
Table 2. Cell cycle analysis of L1210, HL-60 and U-937 leukemia cells 
treated with 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline (BMAQ) for 24 h
BMAQ [µM] G0/G1 S G2/M
L1210
0 44.08 ± 4.26 50.40 ± 4.84 5.53 ± 0.47
13.0 38.37 ± 3.75 52.29 ± 4.97 9.34 ± 0.76
26.0 38.71 ± 3.74 51.63 ± 4.87 9.65 ± 0.83
52.0 35.39 ± 3.47* 54.10 ± 5.17 10.51 ± 0.97*
HL-60
0 49.86 ± 3.47 38.83 ± 3.51 11.31 ± 0.95
13.0 46.08 ± 3.98 39.64 ± 3.02 14.28 ± 0.98
26.0 47.58 ± 4.00 39.29 ± 3.24 13.13 ± 1.00
52.0 46.38 ± 4.10 39.37 ± 2.95 14.25 ± 1.23
U-937
0 43.19 ± 4.21 41.71 ± 3.86 15.10 ± 1.16
13.0 52.90 ± 4.68* 41.44 ± 3.97 5.66 ± 0.41*
26.0 55.78 ± 4.95* 40.13 ± 3.78 4.10 ± 0.26*
52.0 57.47 ± 5.01* 35.73 ± 2.98 6.81 ± 0.51*
Note. Data represent mean values ± s.d. of three independent experiments. 
*P < 0.05.
N�mero�s st�dies have demonstrated that apop-
tosis may be involved in cell death ind�ced by different 
chemotherape�tic agents. Apoptosis can be exec�ted 
thro�gh two basic signalling pathways: one is mediated 
by death receptors on the cell s�rface and the other 
is mediated by mitochondria [�6� �7]. Acc�m�lating 
evidence reveals that the efficacy of antit�mor agents 
is related to the intrinsic propensity of the t�mor cells to 
respond to partic�lar agents by apoptosis. Therefore� in 
the next experiments we analysed BMAQ-treated le�-
kemia cells for apoptotic DNA fragmentation� apoptotic 
bodies formation and activation of caspase-�. We fo�nd 
that all le�kemia cells treated with BMAQ are presenting 
typical apoptotic markers� as intern�cleosomal DNA frag-
mentation �see Fig. ��� apoptotic bodies formation �cells 
had �ndamaged cytoplasmic membrane� �see Fig. �� 
and activation of caspase-� �see Fig. ��. O�r findings are 
consistent with previo�s st�dies demonstrating the ability 
of some q�inazoline derivatives to ind�ce changes in cell 
cycle profile and to ind�ce apoptosis [��7� ��].
In s�mmary� we can concl�de that BMAQ pos-
sesses significant antiproliferative activity and is potent 
ind�cer of programmed cell death in le�kemia cells.
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АНТИПРОЛИФЕРАТИВНOE И ПРОАПОПТОТИЧЕСКOE 
дЕйСТВИЕ 6-БРОМО-2-(МОРФОЛИН-1-ИЛ)-
4-АНИЛИНОИНАЗОЛИНА НА ЛЕйКОЗНЫЕ КЛЕТКИ 
Квиназолины известны как химиопрепараты широкого спектра действия. Цель: на моделях лейкозных клеток линий L1210, 
HL-60 и U-937 изучить противоопухолевую активность нового препарата 6-бромо-2-(морфолин-1-ил)-4-аналиноиназолина 
(BMAQ). Методы: ингибирование роста клеток под действием BMAQ изучали путем подсчета количества клеток, 
окрашенных трипановым синим. Апоптоз и изменения профиля клеточного цикла исследовали с помощью флуоресцентной 
микроскопии, электрофореза ДНК и проточной цитометрии. Активность каспазы-3 определяли колориметрическим 
методом. Результаты: показано, что BMAQ вызывает значительное дозозависимое уменьшение количества лейкозных 
клеток. �ри этом клетки, обработанные BMAQ, погибают путем апоптоза, что подтвер�дается образованием апопто-
тических телец, ме�нуклеосомной фрагментацией ДНК и активацией каспазы-3. Выводы: представленные результаты 
свидетельствуют о том, что BMAQ обладает антипролиферативной и проапоптотической активностью в отношении 
лейкозных клеток in vitro.
Ключевые слова: иназолин, апоптоз, лейкоз.
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